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Abstract 
Background: HbA1C has been a known predictor and diagnostic test for diabetes type 2. 
However, this test has not yet been widely studied in GDM and more importantly no cutoff 
point has been defined for HbA1C in GDM. We investigated the efficacy of screening 
during first and second trimester of pregnancy and defined appropriate cutoff points 
according to HbA1C and FBS for predicting maternal GDM among women with none to 
minimal previously known risk factors. 
Methods: This is a prospective multi-centered cohort study. Individuals were evaluated at 
first trimester, at 20-24 weeks and 24-28 weeks of gestation. GDM tests were done during 
visits and accuracy of each of these measurements was evaluated.  
Results: Overall, 356 entered the study, among which 25 individuals and 30 individuals 
developed GDM during 20-24 and 24-28 weeks of gestation, respectively. HbA1C 
measured during first trimester at a cut-off of 5.35% predicted GDM of 24-28 weeks with 
an accuracy of 85.6%, sensitivity of 80%, and specificity of 80%. Furthermore, at a cut-off 
of 5.75% measured at 20-24 weeks, HbA1C predicted GDM with an accuracy of 94.5%, 
sensitivity of 97%, and specificity of 96%. 
Conclusion: Screening programs during first trimester and at 20-24 weeks of pregnancy, 
using HbA1C, can significantly aid in the early prediction of GDM, even among women 
with no to minimal previously known risk factors, which shows a need for revision in 
current guidelines. 
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Gestational diabetes mellitus (GDM) is the most common metabolic disease of 
pregnancy which has shown an increasing trend over the past years (1). GDM has always 
been defined as any degree of glucose intolerance during any period of pregnancy, 
however the 2016 American Diabetes Association (ADA) guidelines defined GDM as a 
disease of the second and third trimester of pregnancy and any glucose intolerance before 
this time to be considered overt diabetes (2, 3). The condition is associated with multiple 
complications for both the mother and the neonate (born from the mother with GDM), 
some of which include fetal death, fetal macrosomia, dystocia, neonatal hypoglycemia, 
acute distress syndrome, eclampsia and preeclampsia, increased cesarean section and etc. 
(4, 5). Considering the existing guidelines on screening for GDM, some studies have 
shown that despite appropriate control of GDM during third trimester of pregnancy, 
mothers with GDM still show complications associated with the disease such as fetal 
macrosomia. 
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This shows that the patient may have had uncontrolled 
blood glucose prior to the diagnosis of the condition during 
the third trimester of pregnancy which has affected the fetus 
and resulted in complications (6, 7). Accordingly, early 
diagnosis of the condition poses a great dilemma. Moreover, 
those who do not present with any known risk factors for 
GDM, remain to be highly undetected during pregnancy.   
Recently tests to predict GDM have been a subject of 
much attention. Among the predictors of diabetes is HbA1C, 
which has been a known predictor and diagnostic test for 
diabetes type 2 (8). However, this test has not yet been 
widely studied in GDM and more importantly no cutoff 
point has been defined for HbA1C in GDM, especially 
among those who present with no to minimum previously 
known risk factors for diabetes. Considering the 
overwhelming effects of GDM on maternal and neonatal 
health and the urgent need for early diagnosis and control of 
maternal glucose levels, we hypothesized that HbA1C may 
be important for the prediction of GDM. In this study, we 
evaluated the efficacy of HbA1C measured during the first 
and second trimester of pregnancy for the prediction of 
GDM, furthermore, we defined appropriate cutoff points 
according to HbA1C to predict occurrence of GDM. 
 
 
Methods 
Study settings and patients: This is a prospective multi-
centered cohort study conducted in seven health care centers 
affiliated to Zanjan University of Medical Sciences, Zanjan, 
Iran. A total of 432 pregnant women between the ages of 18 
to 35 years old were considered for inclusion in the study. 
All women who had the following criteria were included in 
the study: gestational age of equal or less than 12 weeks at 
first visit, a BMI of between 30 and 18.5 kg/m
2
 and a blood 
pressure of less than 140/90mm/Hg during first visit. 
The exclusion criteria are as follows: Women with a 
positive history of diabetes type one or two or those with a 
previous history of GDM, fetal macrosomia, individuals who 
used medications that affect carbohydrate metabolism such 
as glucocorticoids, patients who had diseases related to 
metabolism of carbohydrates such as liver and thyroid 
related diseases, subjects who used tobacco or alcoholic 
products, participants with anemia or hemoglobinopathies or 
hematologic diseases that affect HbA1C, those with a history 
of high triglyceride or cholesterol, and had multiparity 
pregnancies. 
Study protocol: Recruitment began in April 2015 and 
continued up to April 2016. For the recruitment of patients, 
midwives were trained at all the previously mentioned 
medical health care centers regarding objectives of study, 
patient selection, follow-up of patients, and questionnaires 
related to the study.  
The reasons for the very careful assessment of 
individuals and the very specific inclusion and exclusion 
criteria were to ensure the inclusion of healthy patients, and 
to minimize any bias relating to diabetes risk factors that 
may have affected our primary outcome. 
Primary evaluation of each patient was done by the 
midwifes who were stationed at each medical care center, 
and information regarding age of mother, gestational age, 
gravidity, height, weight, BMI, and blood pressure were 
registered. After which, each patient was referred to one of 
four medical laboratories affiliated to Zanjan University of 
Medical Sciences. Blood samples were obtained for 
evaluation of complete blood count (CBC), fasting blood 
sugar (FBS), high density lipoprotein (HDL), low density 
lipoprotein (LDL), triglyceride (TG), and HbA1C. In cases 
that any of the blood parameters were higher than the normal 
standard limits for the first trimester of pregnancy (9), those 
individuals were excluded from the study. 
Measurements: All samples obtained were stored in 
oxalated tubes and kept in appropriate freezers at the medical 
care centers and were then transferred to Valiasr Hospital 
which is the central hospital in Zanjan city, Iran. For 
evaluating HbA1C status, the NGSP method (according to 
the 2016 ADA guidelines) was utilized using the Nycocard 
kit (Alere Inc., Austria). For the quantitative assessment of 
glucose levels, the Glucose GOD kit (PARS AZMUN coop., 
Tehran, Iran) using the photometry method, was utilized. For 
the evaluation of HDL, cholesterol and TG levels, the Bionik 
kit (Bionik, Tehran, Iran) was applied. For measurement of 
CBC and Hb the Sysmex XP-300™ (Japan) cell count 
machine was used. 
Follow-up studies: Individuals who entered the study, were 
given follow-ups. At 20-24 weeks of gestational age, patients 
were re-examined and oral glucose tolerance test (OGTT) 
with 75 mg glucose was done (10). For the evaluation of 
glucose levels, individuals were asked to fast eight hours 
prior to the tests. Initially, FBS was measured, after which 
individuals were given 75 mg of oral glucose, and blood 
glucose levels were checked one hour (1 hour OGTT) and 
two hours (2 hour OGTT) after glucose consumption. During 
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this stage of follow-up, HbA1C was checked for the second 
time, in addition systolic and diastolic blood pressures were 
also re-measured. All patients who were diagnosed with 
GDM during the 20-24 week follow-up, were referred to 
nutritionists and given appropriate treatments. 
During a second follow-up at 24-28 weeks, all OGTT's 
and physical examinations were repeated, however HbA1C 
was not measured and in case of diagnosis of GDM based on 
OGTT, those individuals would then be referred to an 
endocrinologist for treatment. During follow-up, if a patient 
would have an abortion, premature labor, or intrauterine fetal 
death, that individual would be excluded from the study. In 
addition, the patients were followed-up during birth and 
information on pregnancy related complications such as 
eclampsia, bleeding, cesarean section, and premature birth 
was registered. 
Diagnosis: For the diagnosis of GDM, the ADA guidelines 
2016 were used. Accordingly, any patient who had FBS of 
more than 92mg/dl, 1 hour glucose level ≥180mg/d and 2 
hour glucose level of ≥153mg/d, was considered GDM (3). 
Objectives of study: The main goals of this registry 
included: 1) to evaluate the efficacy of early assessment (first 
trimester) of GDM according to HbA1C among women with 
no previously established risk factors or women with little 
risk factors for development of GDM, 2) to determine a 
cutoff point for HbA1C measured at first and second 
trimester of pregnancy, for the prediction of GDM. 
Data collection: Data were collected at the mentioned health 
care centers and were then stored at the Metabolic Disease 
Research Center affiliated to Zanjan University of Medical 
Sciences, Zanjan, Iran. The data base was managed by a 
team at the research center and data entry was monitored 
carefully. 
Outcome measures: Information regarding age, body mass 
index (BMI), systolic and diastolic blood pressure measured 
during three different intervals, triglyceride, cholesterol, high 
density lipoprotein (HDL), low density lipoprotein (LDL), 
hemoglobin levels (Hb), FBS, 1 hour and 2 hour OGTT 
tests, HbA1C, complication including number of cesarean 
sections, bleeding, fetal death and fetal macrosomia, were 
registered for each patient. 
Sample size calculation: Sample size was calculated 
considering a type one error of 0.05, a p of 0.1 and an effect 
size of 0.03% considering HbA1C as the primary outcome. 
Accordingly, a sample size of 400 was needed for the study.  
Statistical analysis: Data were analyzed using the SPSS
®
 
software for windows
®
, Version 16, (SPSS Inc., Chicago, IL, 
USA).  
For used the comparison of normally distributed quantitative 
variables between any two groups, the independent t-test was 
and for variables without a normal distribution, the Mann-
Whitney test was employed. For comparison of qualitative 
variables between groups, the chi-square and Fisher's exact 
test were applied.  
For the comparison of data during follow-up (repeated 
variables) in a single group, the paired t-test and repeated 
measurement test were utilized. Pearson's correlation was 
used to evaluate the association between glucose 
measurement indexes (FBS, 1hour and 2 hour OGTT, and 
HbA1C) during all follow-ups. To predict the development 
of GDM during 20-24 weeks and 24-28 weeks of pregnancy, 
the receiver operating curve (ROC) analysis was used to 
estimate appropriate cutoff point based on HbA1C measured 
during the first trimester and 20-24 weeks of gestation, 
furthermore, an appropriate cutoff was also defined for FBS 
as well. 
The logistic regression analysis was used to evaluate risk 
factors for the development of GDM during both follow-up 
periods, separately.  
According to the obtained cutoff points for HbA1C and 
based on previous literature, the risk factors obtained in the 
previous logistic regression model were transformed into 
categorical variables and the regression analysis was 
repeated to obtain relative risk (RR) for prediction of GDM. 
A p-value of less than 0.05 was considered statistically 
significant. 
 
 
Results 
Initially 432 individuals were recruited for the study. 
During a follow-up, a total of 18 patients did not continue 
the follow-up and 58 cases were withdrawn from the study. 
In the end, 356 individuals remained in the study. As this 
was a cohort registry and participants were followed 
carefully, no missing data existed regarding any of the 
measured variables. Patients' baseline characteristics are 
shown in table 1.  
Overall, 25 individuals and 30 individuals developed 
GDM during 20-24 weeks and 24-28 weeks of gestational 
age, respectively. 
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Table 1. Comparison of baseline and clinical characteristics between those diagnosed with gestational diabetes mellitus at 
first trimester and 20-24 weeks of gestation and normal individuals. 
Variables Total  
(n=356) 
GDM g1* 
(n=25) 
GDM g2**  
(n=30) 
Normal  
(n=301) 
p-value 
(g1 and normal) 
p-value 
(g2 and normal) 
Age 26.4 ± 4.3 27.1 ± 4.3 27.7 ± 4.2 26.3 ± 4.3 0.398 0.061 
BMI 25.3 ± 3.7 27.8 ± 3.2 28.2 ± 2.8 25.1 ± 3.6 <0.001 <0.001 
Systolic BP1 101.2 ±9.9 102.4 ± 9.2 105.6 ± 9 101.1 ± 10 0.389 0.011 
Systolic BP2 103.6 ±1.2 113.6 ± 16.5 113.5 ± 16.5 102.8±12.2 0.002 0.001 
Systolic BP3 102.1 ±1.3 114.7 ± 18.1 113.9 ± 17.3 101.1±12.7 <0.001 <0.001 
Diastolic BP1 64.7 ± 8.3 66.4 ± 7.8 68.8 ± 7.5 64.5 ± 8.3 0.261 0.004 
Diastolic BP2 67.8 ± 8.1 74.4 ± 10.9 74.3 ± 9 67.3 ± 7.6 <0.001 <0.001 
Diastolic BP3 67.4 ± 9.1 76.2 ± 10.5 76.9 ± 10 66.7 ± 8.6 <0.001 <0.001 
TG 95.1 ±33.2 101.8 ± 40 102.4 ± 32.7 94.6 ± 33.6 0.474 0.238 
Cholesterol 139.8±326 150.6 ± 26.6 138.8 ± 34.2 139 ± 32.8 0.086 0.865 
HDL 49.1±11.6 49.3 ± 10.7 47.2 ± 8.2 49.1 ± 11.6 0.713 0.688 
LDL 76.32±2.19 80.6 ± 17.8 76.2 ± 20.2 76 ± 22.2 0.31 0.972 
Hb 12.8±0.87 12.8 ± 0.6 13 ± 0.7 12.8 ± 0.8 0.713 0.167 
HbA1C1 5.083±0.44 5.81 ± 0.42 5.67 ± 0.41 5.02 ± 0.38 <0.001 <0.001 
HbA1C2 5.138±0.54 6.17 ± 0.65 6.17 ± 0.52 5.06 ± 0.44 <0.001 <0.001 
HbA1C1≥5.3% 119 (33.4) 23 (92) 24 (80) - <0.001 <0.001 
HbA1C1≤5.3% 237 (66.6) 2 (8) 6 (20) - 
Complications        
Cesarean section 69 10 (14.5) 12 (17.4) 59 (85.5) 0.015 0.006 
Bleeding 15 4 (26.7) 6 (40) 11 (73.3) 0.015 0.001 
Fetal death 5 2 (40) 1 (20) 3 (60) 0.042 0.358 
fetal macrosomia 28 11 (39.3) 14 (50) 17 (60.7) <0.001 <0.001 
GDM: gestational diabetes mellitus; BMI: body mass index; BP: blood pressure; TG: triglyceride; HDL: high density cholesterol; LDL: low density cholesterol; 
HbA1C: hemoglobin A1C 
*GDM g1 are those who were diagnosed with GDM during first trimester   GDM g2 are those who were diagnosed with GDM during 20-24 weeks of gestation. 
Furthermore, BP one, two and three show first trimester, 20-24 weeks and 24-28 weeks of gestation. 
 
Comparison of those diagnosed with GDM during 20-24 
weeks of gestational age and those diagnosed during 24-28 
weeks with the normal population showed that, individuals 
with GDM, had significantly higher systolic and diastolic BP 
during both 20-24 weeks and 20-28 weeks (p<0.05). These 
individuals had significantly higher HbA1C at both 
measurements compared to that of the normal population 
(p<0.001).  
Those with GDM further showed a significant increase in 
HbA1C from the first trimester to the 20-24 weeks of follow-
up (5.81%±0.42% vs. 6.17%±0.65% for the 20-24 GDM 
group, and 5.67%±0.41% vs. 6.17%±0.52% for the 24-28 
week GDM group, p<0.001). Regarding pregnancy-related 
complications, those with normal pregnancies had 
significantly higher rates of cesarean sections (P=0.006),  
 
postpartum bleeding (P=0.001), and fetal macrosomia 
(p<0.001) compared to those diagnosed with GDM. In the 
20-24 week diagnosed GDM group, fetal death rates were 
higher compared to both the normal group (p=0.042) and the 
24-28 week diagnosed GDM group (20% vs. 40%) (table1). 
FBS (measured during first visit), 1 hour OGTT, 2 hour 
OGTT, and HbA1C consecutive measurements all showed a 
significant increase among mothers in the study during 
follow-ups (table 2). Blood glucose-related measurements 
were correlated, results showed that HbA1C measured at 
first visit and at 20-24 weeks were correlated with all related 
glucose measurement tests (FBS, 1 hour and 2 hour OGTT 
during all visits, p<0.001). HbA1C at first visit was more 
strongly correlated with HbA1C at 20-24 weeks (r=0.639), 
followed by OGTT at 24-28 weeks (r=334) and OGTT at 20-
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24 weeks (r=0.295), respectively. HbA1C at 20-24 weeks 
was more correlated with HbA1C at first visit, followed by 
OGTT at 24-28 weeks (r=438) and 1 hour OGTT at 24-28 
weeks (r=0.394), respectively (table 3). 
 
Table 2. Gestational diabetes mellitus related tests during first visit and follow-up visits. 
Variables  First trimester 20-24 wks 24-28 wks p-value 
FBS  76.28 ± 6.22 79.11 ± 8.09 80.75 ± 6.8 <0.001 
1hr OGTT   130 ± 28.5 132.9 ± 26.4 0.001 
2hr OGTT   117.9 ± 20 119 ± 18.6 0.091 
HbA1C  5.08 ± 0.44 5.13 ± 0.54  <0.001 
GDM based on FBS  14 (56) 18 (60)  
 1hr OGTT  17 (68) 17 (56.7)  
 2hr OGTT  12 (48) 13 (43.3)  
 FBS and 1hr OGTT  7 (28) 9 (30)  
 1hr OGTT and  2hr OGTT  9 (36) 8 (26.4)  
 FBS and 2hr OGTT  5 (20) 5 (16.6)  
 FBS and 1hr OGTT & 2hr OGTT  3 (12) 3 (10)  
 Overall   25 (100) 30 (100)  
FBS: fasting blood sugar; OGTT: oral glucose tolerance test; HbA1C: hemoglobin A1C; GDM: gestational diabetes mellitus 
 
Table 3. Correlation between blood glucose measurement indexes during first visit and all follow-up periods.* 
HbA1C1 FBS1 FBS2 1hr 
OGTT1 
2hr 
OGTT1 
HbA1C2 FBS3 1hr 
OGTT2 
2hr 
OGTT2 
 
1 0.256* 0.295 0.278* 0.280* 0.639 0.334 0.273* 0.232* HbA1C1 
 1 0.464 0.511 0.483 0.281 0.396 0.456 0.401 FBS1 
  1 0.595 0.517 0.383 0.536 0.556 0.524 FBS2 
   1 0.843 0.351 0.483 0.869 0.742 1hr OGTT1 
    1 0.315 0.449 0.756 0.792 2hr OGTT1 
     1 0.438 0.394 0.327 HbA1C2 
      1 0.582 0.273 FBS3 
       1 0.824 1hr OGTT2 
        1 2hr OGTT2 
 HbA1C: hemoglobin A1C; FBS: fasting blood glucose; OGTT: glucose tolerance test 
*Numbers associated with values demonstrate time of measurements as followed: FBS1 measured at first trimester; FBS2 
measured at 20-24 weeks of gestation, FBS3 measured at 24-28 weeks; OGTT1 measured at 20-24 weeks; OGTT2 measured at 24-
28 weeks; HbA1C1 measured at first trimester; HbA1C2 measured at 20-24 weeks. 
 
As the main outcome of the study, the ROC curve 
analysis showed that HbA1C during first visit (during the 
first trimester) at a cutoff of 5.35% can predict GDM of 24-
28 weeks of pregnancy with an accuracy of 85.6%, 
sensitivity of 80% and specificity of 80%. For the diagnosis 
of GDM at 20-24 weeks of pregnancy, HbA1C at first visit 
at a cutoff of 5.45%, had an accuracy of 93.3%, sensitivity of 
87%2, and specificity of 92%. At a cutoff of 5.75%, HbA1C  
measured during 20-24 weeks had an accuracy of 94.5%, 
sensitivity of 97%, and specificity of 96% for the diagnosis  
 
of GDM of 24-28 weeks. Furthermore, HbA1C at 20-24 
weeks also showed an accuracy of 91.4%, sensitivity of 97% 
and specificity of 92% at a cutoff of 5.85% for diagnosis of 
GDM at 20-24. FBS was also used to predict GDM at 20-24 
weeks and 24-28 weeks, and accordingly, a cutoff of 
78.5mg/dl could estimate GDM at 24-28 weeks with an 
accuracy of 74.4%, sensitivity of 64% and specificity of 
73%, and a cutoff of 79.5mg/dl could predict GDM at 20-24 
weeks of pregnancy with an accuracy of 80.9%, sensitivity 
of 76% and specificity of 76%. Results also showed that 
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OGTT diagnosed at 20-24 weeks of pregnancy had a 
sensitivity of 53% and specificity of 97% for the diagnosis of 
GDM during 24-28 weeks of follow-up. 
We used a regression analysis to predict risk factors 
associated with GDM at both follow-ups. Results showed 
that two factors of BP at 20-24 weeks (beta: 3.73, P=0.001) 
and HbA1C at first trimester (beta: 4.167, p<0.001) were risk 
factors for GDM at 20-24 weeks, moreover BMI (beta: 
0.184, P=0.003), BP at 20-24 weeks (beta: 1.689, P=0.019) 
and HbA1C at first trimester (beta: 2.25, p<0.001) were risk 
factors for the development of GDM at 24-28 weeks of 
pregnancy. When we repeated the regression analysis 
according to categorical variables, BMI higher and equal to 
27 kg/m
2
 also presented as a risk factor (RR: 3.4, 95% CI = 
1.23-9.49) for the development of GDM at 20-24 weeks of 
pregnancy (table 4).  
 
Table 4. Regression models for estimating risk factors of developing GDM. * 
 
Variables Beta RR 95% Confidence interval p-value 
Regression model no. 1     
20-24 wks     
BMI 0.118 - - 0.089 
Age 0.559 - - 0.345 
BP2† 3.733 - - 0.001 
HbA1C1 4.167 - - <0.001 
24-28 wks     
BMI 0.184 - - 0.003 
Age 0.60 - - 0.242 
BP2 1.689 - - 0.019 
HbA1C1 2.25 - - <0.001 
Logistic regression no. 2     
20-24 wks     
BMI≥27  3.4 1.23-9.49 0.018 
age≥25  1.7 0.54-5.62 0.34 
BP2≥140/90  37.1 3.56-387.4 0.002 
HbA1C1≥5.3%  56.6 6.95-462.3 0.001 
24-28 wks     
BMI≥27  5.92 2.3-15.26 0.001 
age≥25  1.18 0.65-5.03 0.25 
BP2≥140/90  4.75 1.08-20.82 0.039 
HbA1C1≥5.3%  9.1 3.38-24.64 0.001 
RR: relative risk; BMI: body mass index; BP: blood pressure: HbA1C: hemoglobin A1C 
*Two regression models have been introduced. The first represent independent variables as quantitative data and in the second model values have been redefined 
according to appropriate cut-off values obtained both in the study and from previous studies. 
 †Numbers indicate time of measurements as followed: BP2 as BP measured during 20-24 weeks of gestation; HbA1C1 as measured during 20-24 weeks of 
gestation. 
 
Discussion 
Herein we developed a cutoff point based on HbA1C and 
FBS of the first trimester and 20-24 weeks of gestation  
among pregnant women to predict development of GDM in 
the settings of a cohort study. Considering the effects of high 
blood sugar on maternal and fetal health during pregnancy,  
 
to the best of the authors' knowledge, this is the first study 
that has evaluated the clinical value of early screening based 
on HbA1C in the setting of a cohort study among women 
with minimal previously known risk factor for development 
of GDM. We screened mothers in the first trimester of 
pregnancy, which was one month earlier than the guidelines 
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reported by the ADA 2016 (11) and WHO 2013 (2), which 
mainly focus on pregnant woman with associated risk factors 
for GDM and we found that HbA1C measured at the first 
trimester at a cut-off of 5.35%, can predict GDM with high 
accuracy (>80%), moreover, HbA1C at a cut-off of 5.75%, 
measured during the second trimester, can predict GDM with 
an accuracy of more 90%.  
A total of 7% and 8.3% of individuals in our study 
developed GDM during 20-24 weeks and 24-28 weeks of 
pregnancy. In a retrospective study in 2014, Fong et al. (12) 
evaluated 526 woman using HbA1C of first trimester, they 
compared those with HbA1C of less than 5.7% and those 
with HbA1C of 5.7-6.4%. They found those with HbA1C of 
5.7-6.4% to have a 2.4 higher chance of developing GDM. In 
the latter study, OGTT with 100 gr of oral glucose was used 
to determine GDM, more importantly, the cutoffs used for 
HbA1C were predetermined according to previous cutoffs in 
non-pregnant patients. We defined appropriate cutoff points 
according to our own cohort follow-up, in addition, we 
defined cutoff points in normal women without any to 
minimal previous risk factors for the development of GDM 
to advocate a guideline for early screening using HbA1C of 
first trimester among the apparently healthy pregnant 
women. We found that HbA1C measured at the first 
trimester was high among both the groups of individuals 
who were diagnosed with GDM during 20-24 weeks and 24-
28 weeks of pregnancy. This finding is valuable as it shows 
that HbA1C at first trimester can be a predictor of GDM not 
only among high risk individuals, but among healthy 
mothers with minimal GDM related risk factors as well. 
Our final results showed that a cut-off of 5.3% for 
HbA1C at first trimester was able to predict 80% of cases of 
GDM at 24-28 weeks of pregnancy with an accuracy of 85%. 
When we separately categorized individuals based on having 
an HbA1C of more or less than 5.3%, according to our own 
obtained cutoff points, both GDM groups showed a 
significant difference with the normal population, which 
supports our primary findings that perhaps 5.3% is an 
appropriate cutoff point to perform early screening for 
pregnant women. Additionally, we further evaluated the 
efficacy of HbA1C at 20-24 weeks of pregnancy and found 
that at a cut-off of 5.75%, HbA1C could predict 97% of 
cases of GDM of 24-28 weeks with a an accuracy of 94.5%.  
Rajput (13) evaluated the efficacy of HbA1C measured 
during 24-28 weeks of pregnancy for the diagnosis of GDM 
among 607 women. They found HbA1C at a cutoff of 
≥5.95% to have an accuracy of 80.5%, sensitivity of 28.6% 
and specificity of 97.2% for the diagnosis of GDM. 
Futhermore, at a cutoff of ≥5.45%, HbA1C had a sensitivity 
of 85.7% and specificity of 61.1% for the diagnosis of GDM. 
We found a cutoff of 5.35% and 5.75% for HbA1C at first 
trimester and 20-24 weeks, respectively to be ideal for the 
diagnosis of GDM at 24-28 weeks of gestation. Comparison 
of the two studies, shows that perhaps HbA1C cutoff points 
increase with increased gestational age, and considering that 
insulin resistance increases throughout pregnancy (14) which 
consequently increases mean HbA1C, as shown in our study, 
this finding seems logical. Although it should be kept in 
mind that physiological anemia and increased blood plasma 
which occurs naturally during pregnancy, it can cause 
HbA1C to be lower at the beginning of pregnancy compared 
to non-pregnant women. This was also shown in the study by 
Hiramutsu et al. (15) in 2012, who showed that HbA1C 
decreases during the second trimester of pregnancy and 
increases during the third trimester of pregnancy. This points 
to the importance of defining a specific cutoff point for 
HbA1C during each trimester, as in our study in which we 
defined two different cutoff points once during the first 
trimester of pregnancy as an early screening tool and 
secondly at 20-24 weeks of gestation. 
Another finding which supports the notion of an increase 
of insulin resistance in pregnancy was the increase in FBS 
which was shown to be significant during the first visit (at 
the first trimester) and all follow-up visits. 
From another perspective, our obtained cutoff points for 
HbA1C for the prediction of GDM were 5.35% and 5.75%. 
The first cutoff point included a normal range HbA1C and 
the second included pre-diabetic individuals (in the 
definition of diabetes in normal healthy adults). This finding 
was similar to that of the mentioned study by Rajbut (13) 
who also found that at a cutoff of ≥5.45%, HbA1C had an 
acceptable sensitivity and specificity for diagnosis of GDM. 
The reason for this may be attributed to the previously 
mentioned physiological anemia and increased blood plasma 
which causes a decrease in HbA1C compared to non-
pregnant women (14, 15), thus a seemingly normal HbA1C 
showed to be a strong predictor of GDM in our study. 
Another interesting finding was the cutoff point defined for 
FBS at first trimester, as those who had FBS of higher than 
79.5mg/dl, developed GDM at 24-28 weeks of pregnancy 
with a sensitivity and specificity of 76% and an accuracy of 
81%. This shows that mothers who have a FBS of higher 
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than 79.5mg/dl, would benefit from an earlier screening test 
(for example at 20-24 weeks) for GDM. In our correlation 
analysis we found a positive and significant association 
between FBS measured at first trimester and all consecutive 
visits with HbA1C at first visit and at 20-24 weeks of 
gestation, this shows that individuals who present with high 
HbA1C at first visit have a concomitant high FBS. 
Although we excluded individuals with most previously 
known risk factors for GDM such as obesity, hypertension 
and old age, individuals who ended up developing GDM in 
our study had higher BMI, and systolic and diastolic BP 
compared to the normal group, although all were in the 
normal range. On one hand, HbA1C is a means of 
controlling blood glucose among those with proven diabetes, 
on the other hand, it shows the status of glucose control 
during past months. Accordingly, based on our findings, 
development of GDM (similar to that of complication which 
develops due to uncontrolled BS due to GDM), may be 
highly affected from previous glucose control, which is then 
predictable with HbA1C testing. Our final regression model 
showed that individuals with an HbA1C of ≥5.3% at first 
trimester, based on our obtained cutoff point, have a 9.1 time 
higher risk of developing GDM during 24-28 weeks of 
gestation.  
This study was not without limitation. As pregnancy 
related complications are not very common, our sample size 
in the GDM groups was relatively small considering these 
outcomes as we calculated our sample size according to our 
primary outcome which was to obtain an appropriate cutoff 
point based on HbA1C for prediction of GDM, and 
comparisons of complication may not have been accurate. 
Like the higher recorded complications among those with 
normal pregnancies, which is probably attributable to the 
small sample sizes in the GDM groups. On the other hand, 
this was a cohort study and all individuals in the study were 
followed for the development of GDM, which renders 
valuable results regarding outcomes. We used the ADA 
guidelines for the definition of our GDM cases, however, 
other guideline also exists which may render different results 
regarding cutoff points. Our study included women who 
were overweight (BMI between 25 kg/m
2
), and these 
individuals may have had a minor risk factor for the 
development of GDM and would not be considered as 
completely without risk factor. This was also shown in our 
regression model which showed a BMI of more than 27 to be 
a significant predictor of GDM. Although this does not 
compromise the main objective of our study, which was to 
define an appropriate cutoff point according to HbA1C 
during the first and second trimester for predicting GDM. 
Considering that the Iranian guideline for obstetric screening 
advises all pregnant women to have FBS checked at the 
beginning of their pregnancy and does not separate those 
classified as low and high risk, in this study we showed that 
perhaps HbA1C measured during the first trimester may 
significantly aid in predicting those who may develop GDM 
later in their pregnancy. Moreover, we found that FBS at a 
cutoff of 79.5mg/dl could predict GDM at 20-24 weeks of 
gestation, so although screening is advised according to our 
country guidelines, our study adds important information on 
the specific cutoff point at which GDM will be predictable. 
Another issue relates to the cost-effectiveness of 
evaluating HbA1C for all women during first trimester 
despite any associated risk factors. Although HbA1C during 
the second trimester was able to detect GDM development 
with more than 95% accuracy, sensitivity and specificity, we 
found that this method of screening during the first trimester 
had an accuracy of 85% and more importantly a sensitivity 
of specificity of 80%, meaning that 20% of individuals 
would not be detected on initial screening. This requires 
studies to be conducted focusing on the cost-effectiveness of 
the current result to precisely evaluate the exact 
implementation of these findings in clinical guidelines.  
As we did not separate those with BMI higher than 25-30 
kg/m2 and those under 25Kg/m2, our cutoff points were 
similar for all pregnant women, even those who were 
overweight. As guidelines recommend OGTT during 24-28 
weeks, we first performed this at 20-24 weeks. However, our 
diagnosis of GDM was mainly based on the OGTT test 
performed during 24-28 weeks which was according to the 
previously mentioned ADA guidelines, on the other hand we 
performed another OGTT test at 20-24 weeks of gestation. 
The main purpose of this endeavor, according to our 
objective of study, was to determine the value of earlier 
screening programs in the diagnosis of GDM both at the 
recommended and at an earlier time. More importantly, this 
does not compromise our main objective of study, which was 
to evaluate the efficacy of earlier screening based on HbA1C 
on the diagnosis of GDM. We did not consider drop-out 
rates, thus, the final total number of individuals who entered 
the study was below the calculated sample size. Fortunately, 
this did not affect our final outcome significance. Although 
recommendation to perform GDM screening in 24 weeks is 
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mainly based on changes in blood sugar metabolism after 
half pregnancy, we performed our tests using HbA1C at an 
earlier time to show that early levels of HbA1C may be a 
strong predictor of GDM in the second and third months of 
pregnancy. In conclusion according to our findings, starting 
screening programs during the first trimester and at 20-24 
weeks of pregnancy using HbA1C, can significantly aid in 
the earlier detection of GDM, even among women with 
minor previously known risk factors. More importantly, we 
found that an HbA1C of ≥5.3% in the first trimester and 
HbA1C of ≥5.75% at 20-24 weeks of gestation can be a 
good predictor of GDM with high accuracy. 
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